![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Posts
;
CONGRESS | #EHA2025 | PRESENTATION
Shira Dinner, @NorthwesternU, shares subgroup analysis results from the phase III ECOG-ACRIN E1910 trial of blinatumomab addition to consolidation in young adult (<55 years) patients with BCR::ABL1-negative B-ALL (N = 277).
Outcomes in blina vs…
Petros Grivas (@PGrivasMDPhD), Joan Schiller of @OUCHIntl, Zachary Avigan (@Zach_Avigan) receive ECOG-ACRIN (@eaonc) 2025 scientific leadership, mentorship awards
ComboMATCH/EAY191-E5 tests how well #sotorasib with or without #panitumumab can treat patients with advanced #SolidTumors. For more information: https://bit.ly/combomatch-e5 cc: @NCItreatment, @kspencer725, @DocDustyD #PrecisionMedicine
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
38
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
